MORE ON RELAPSES AFTER PAXLOVID TREATMENT FORÂ COVID-19
Some people treated for COVID-19 with Paxlovid experience a relapse in illness shortly after stopping treatment – a recurrence of symptoms and a positive antigen test – sometimes after the test became negative. Relapses vary in severity, from very mild and brief to worse than the initial illness. Pfizer offered additional details from their EPIC-HR study, citing that late viral rebounds occurred in roughly the same proportion of treated and untreated participants in their trial — around 2%. Additionally, FDA and Pfizer have made it clear that the people who relapse are in fact eligible for re-treatment under the Emergency Use Authorization (EUA).
Full Access: NJEM
ABBOTT OBTAINS FDA CLEARANCE FOR FIRST TEST THAT SIMULTANEOUSLY DETECTS FOUR COMMON SEXUALLY TRANSMITTED INFECTIONS (STIS) AS CASES ARE ON THE RISE
The Alinity m STI test for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) requires one swab sample or a urine sample collected in a healthcare setting by either a clinician or by the patient. The test runs on Abbott’s Alinity m system — the company’s most advanced high-volume laboratory molecular instrument. Alinity m uses polymerase chain reaction (PCR) technology, with high sensitivity in detecting infectious diseases. This test can help healthcare providers save time, increase efficiency and better serve patients.
Full Access: Abbott
RISK OF INFECTION AND HOSPITALIZATION AMONG VACCINATED AND UNVACCINATED CHILDREN AND ADOLESCENTS IN NEW YORK AFTER THE EMERGENCE OF THE OMICRON VARIANT
Linking 4 New York state databases for COVID-19 vaccinations, cases, and admissions, this analysis compared 2 outcomes among fully vaccinated (≥14 days after primary series completion) vs unvaccinated youth (partially vaccinated excluded) in the age groups 5 to 11 and 12 to 17 years. The risks of infection and hospitalization were elevated for unvaccinated vs vaccinated children aged 5 to 11 and 12 to 17 years, although the risk declined as Omicron became more prevalent.
Full Access: JAMA
Â
